Perumal, J., Fox, R. J., Balabanov, R., Balcer, L. J., Galetta, S., Makh, S., . . . Lee, L. (2019). Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: A prespecified 2-year interim analysis of STRIVE. BMC Neurol.
Citação norma ChicagoPerumal, Jai, Robert J. Fox, Roumen Balabanov, Laura J. Balcer, Steven Galetta, Shavy Makh, Sourav Santra, Christophe Hotermans, and Lily Lee. "Outcomes of Natalizumab Treatment Within 3 years of Relapsing-remitting Multiple Sclerosis Diagnosis: A Prespecified 2-year Interim Analysis of STRIVE." BMC Neurol 2019.
Citação norma MLAPerumal, Jai, et al. "Outcomes of Natalizumab Treatment Within 3 years of Relapsing-remitting Multiple Sclerosis Diagnosis: A Prespecified 2-year Interim Analysis of STRIVE." BMC Neurol 2019.